| Ribosome biogenesis in eukaryotes |
2.31 |
0.00e+0 |
52/108 (48.15%) |
NXT2;POP7;GNL3;...
|
| Alanine, aspartate and glutamate metabolism |
2.15 |
3.85e-3 |
27/37 (72.97%) |
ASNS;GOT1;ASPA;...
|
| Glycine, serine and threonine metabolism |
1.96 |
5.13e-3 |
31/40 (77.5%) |
MAOB;GATM;DLD;...
|
| Citrate cycle (TCA cycle) |
1.85 |
1.35e-2 |
30/30 (100%) |
IDH3A;DLD;DLAT;...
|
| Folate biosynthesis |
1.76 |
2.16e-2 |
23/26 (88.46%) |
GCH1;PTS;MOCOS;...
|
| Glyoxylate and dicarboxylate metabolism |
1.74 |
2.31e-2 |
23/30 (76.67%) |
PCCB;DLD;ACAT2;...
|
| Propanoate metabolism |
1.70 |
3.52e-2 |
30/34 (88.24%) |
PCCB;DLD;ACAT2;...
|
| RNA transport |
1.69 |
3.85e-2 |
128/186 (68.82%) |
EIF2S3;TARDBP;EIF2S1;...
|
| Taurine and hypotaurine metabolism |
1.69 |
3.51e-2 |
8/11 (72.73%) |
ADO;CDO1;GAD2;...
|
| Nitrogen metabolism |
1.67 |
3.70e-2 |
16/17 (94.12%) |
CA2;GLUD2;CPS1;...
|
| Homologous recombination |
1.65 |
4.27e-2 |
35/41 (85.37%) |
RAD51C;RAD51;RAD52;...
|
| Non-homologous end-joining |
1.64 |
4.56e-2 |
11/13 (84.62%) |
FEN1;DNTT;PRKDC;...
|
| Pentose and glucuronate interconversions |
1.64 |
4.32e-2 |
17/34 (50%) |
UGT2B15;DCXR;UGP2;...
|
| Yersinia infection |
-1.65 |
4.93e-2 |
120/137 (87.59%) |
GNAQ;FYB1;PIP5K1C;...
|
| HIF-1 signaling pathway |
-1.66 |
4.70e-2 |
105/109 (96.33%) |
EGF;PFKP;LDHA;...
|
| Relaxin signaling pathway |
-1.66 |
4.65e-2 |
114/129 (88.37%) |
GNAI2;COL1A1;NOS2;...
|
| Rap1 signaling pathway |
-1.66 |
4.85e-2 |
184/210 (87.62%) |
IGF1R;EFNA3;GNAI2;...
|
| Sphingolipid metabolism |
-1.67 |
4.16e-2 |
32/49 (65.31%) |
SPTLC1;PLPP2;ARSA;...
|
| Notch signaling pathway |
-1.68 |
4.30e-2 |
49/59 (83.05%) |
HEYL;DVL1;PSEN1;...
|
| Complement and coagulation cascades |
-1.68 |
4.51e-2 |
76/85 (89.41%) |
F5;F3;ITGAM;...
|
| Regulation of actin cytoskeleton |
-1.71 |
3.13e-2 |
185/218 (84.86%) |
PTK2;ITGA9;BAIAP2;...
|
| Pathways in cancer |
-1.73 |
2.51e-2 |
474/531 (89.27%) |
MITF;PGF;CCND2;...
|
| Proteoglycans in cancer |
-1.74 |
2.51e-2 |
172/205 (83.9%) |
FZD2;IGF1R;DROSHA;...
|
| Bladder cancer |
-1.76 |
1.93e-2 |
40/41 (97.56%) |
CXCL8;MMP9;TP53;...
|
| Pathogenic Escherichia coli infection |
-1.76 |
2.06e-2 |
152/197 (77.16%) |
CYFIP2;CLDN6;RAB1A;...
|
| Transcriptional misregulation in cancer |
-1.77 |
1.95e-2 |
158/192 (82.29%) |
GADD45G;DDX5;REL;...
|
| Pertussis |
-1.77 |
2.10e-2 |
64/76 (84.21%) |
MYD88;GNAI2;NOS2;...
|
| Basal cell carcinoma |
-1.79 |
1.78e-2 |
41/63 (65.08%) |
GADD45G;BMP4;FZD2;...
|
| Mucin type O-glycan biosynthesis |
-1.80 |
1.40e-2 |
20/36 (55.56%) |
GALNT1;GCNT1;B3GNT3;...
|
| Arrhythmogenic right ventricular cardiomyopathy |
-1.81 |
1.31e-2 |
70/77 (90.91%) |
CACNB2;CDH2;TCF7;...
|
| Human papillomavirus infection |
-1.85 |
9.24e-3 |
284/331 (85.8%) |
PPP2R5E;MAML1;TRADD;...
|
| MicroRNAs in cancer |
-1.87 |
4.45e-3 |
146/310 (47.1%) |
CCND2;EFNA3;PDGFRA;...
|
| Protein digestion and absorption |
-1.89 |
3.39e-3 |
78/103 (75.73%) |
COL13A1;COL6A1;COL9A2;...
|
| PI3K-Akt signaling pathway |
-1.99 |
1.98e-3 |
317/354 (89.55%) |
IBSP;EIF4E2;GNG7;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-2.00 |
2.38e-3 |
97/100 (97%) |
PIM1;PRKCB;SMAD3;...
|
| Small cell lung cancer |
-2.06 |
2.97e-3 |
90/92 (97.83%) |
CDKN1B;TRAF5;TP53;...
|
| Amoebiasis |
-2.14 |
0.00e+0 |
99/102 (97.06%) |
LAMC3;RAB7A;COL1A1;...
|
| Focal adhesion |
-2.30 |
0.00e+0 |
180/201 (89.55%) |
PDPK1;PTK2;ITGA9;...
|
| ECM-receptor interaction |
-2.75 |
0.00e+0 |
80/88 (90.91%) |
CHAD;HSPG2;COL6A1;...
|
